Skip to main content
The Journal of Biological Chemistry logoLink to The Journal of Biological Chemistry
. 2009 Sep 30;284(51):35758–35768. doi: 10.1074/jbc.M109.051409

The Divalent Metal Transporter Homologues SMF-1/2 Mediate Dopamine Neuron Sensitivity in Caenorhabditis elegans Models of Manganism and Parkinson Disease*

Raja Settivari ‡,§, Jennifer LeVora , Richard Nass ‡,§,¶,1
PMCID: PMC2791006  PMID: 19801673

Abstract

Parkinson disease (PD) and manganism are characterized by motor deficits and a loss of dopamine (DA) neurons in the substantia nigra pars compacta. Epidemiological studies indicate significant correlations between manganese exposure and the propensity to develop PD. The vertebrate divalent metal transporter-1 (DMT-1) contributes to maintaining cellular Mn2+ homeostasis and has recently been implicated in Fe2+-mediated neurodegeneration in PD. In this study we describe a novel model for manganism that incorporates the genetically tractable nematode Caenorhabditis elegans. We show that a brief exposure to Mn2+ increases reactive oxygen species and glutathione production, decreases oxygen consumption and head mitochondria membrane potential, and confers DA neuronal death. DA neurodegeneration is partially dependent on a putative homologue to DMT-1, SMF-1, as genetic knockdown or deletion partially inhibits the neuronal death. Mn2+ also amplifies the DA neurotoxicity of the PD-associated protein α-synuclein. Furthermore, both SMF-1 and SMF-2 are expressed in DA neurons and contribute to PD-associated neurotoxicant-induced DA neuron death. These studies describe a C. elegans model for manganism and show that DMT-1 homologues contribute to Mn2+- and PD-associated DA neuron vulnerability.

Introduction

Manganese is the second most prevalent transition metal and is an essential trace element that is necessary for normal growth and development. The heavy metal is required for a number of biological processes, including amino acid, lipid, and carbohydrate production, and metabolism, and is a cofactor for a diverse set of proteins, including arginases, transferases, hydrolases, ligases, and oxidoreductases (1, 2). Deficiencies in Mn2+, although rare, have been linked with bone malformation, hypertension, osteoporosis, and epilepsy (3, 4).

Mn2+ is also a potent neurotoxicant, and occupational exposure to high concentrations of the metal can result in a neurological condition called manganism (1, 5). Symptoms of manganism include tremors, bradykinesia, rigidity, and facial muscle spasms (1, 6, 7). Mn2+ neurotoxicity has been associated with a number of occupational and environmental exposures. High incidence of manganism has been found in manganese miners and smelters (710). Welders appear to be particularly vulnerable to the disorder as manganese alloys used in the heating and joining of metals may result in the production and inhalation of manganese particles (11). Exposure to Mn2+-based pesticides, including maneb and mancozeb, has also been associated with the development of manganism (1214). Furthermore, significant environmental exposures have been reported with water contamination and possibly with the manganese-containing anti-knock fuel additive methylcyclopentadienyl manganese tricarbonyl (12). Recently, high exposures to Mn2+ have also been associated with psychoactive stimulant preparations for recreational drug use (15, 16).

Epidemiological studies suggest a significant correlation of exposure to high concentrations of Mn2+ and the propensity to develop Parkinson disease (PD)2 (6, 11). PD is characterized by the loss of DA neurons in the substantia nigra and other basal ganglia (17). Individuals with occupational exposure to Mn2+ greater than 20 years have an increased probability to develop PD (18). Combinatorial long term exposures to Mn2+, Fe2+, and aluminum (greater than 30 years) have also been shown to lead to increased likelihood of PD (19). Acute Mn2+ toxicity results in symptoms similar (but not identical) to those seen in patients with PD, including rigidity, tremors, and bradykinesia (1, 7, 11, 20). As in PD, oxidative stress appears to play a significant role in the disorder, and the brain region most susceptible to Mn2+ injury is also sensitive to oxidative stress (2126). Mn2+ toxicity can confer damage to the striatum, reduction of the DA precursor tyrosine hydroxylase, and DA neurodegeneration (2729). The PD-associated pre-synaptic protein α-synuclein has also been proposed to contribute to the pathogenesis of both disorders (3033). Although the molecular bases of manganism and Mn2+-induced toxicity has not been elucidated, in vitro studies of Mn2+ treatments suggest inhibition of the electron transport chain complex-I within the mitochondria and increase in production of reactive oxygen species (ROS) (21, 23, 34). Furthermore, there are significant changes in intracellular antioxidant levels, including GSH, thiols, and catalase (35, 36).

Mn2+ is believed to be transported into the cell via several routes, including voltage-gated and glutamate receptor calcium channels, the transferrin receptor, and the proton-coupled electrogenic divalent metal transporter-1, DMT-1 (37, 38). DMT-1 mediates the transport of divalent ions, including Mn2+, Fe2+, copper, cobalt, lead, and zinc. In yeast, DMT-1 isoforms Smf1p and Smf2p transport Mn2+ across the plasma membrane and intracellular vesicles, respectively (3942). In vertebrates, two of four isoforms of DMT-1 have been identified and are the major transporters involved in absorption of Fe2+ in the intestines (37, 43). Also known as Nramp2 (natural resistance-associated macrophage protein), the transporters are expressed in most tissues and are capable of transporting divalent metal cations (38). Recently, DMT-1 has been implicated in Fe2+-mediated DA neuronal death in PD and vertebrate model systems (44).

The nematode Caenorhabditis elegans is a powerful model system to explore the molecular basis of PD-associated DA neuronal vulnerability and death (45, 46). All of the genes responsible for DA biosynthesis, packaging, and reuptake have recognizable homologs in the worm genome, and genetic, cellular, and functional studies confirm their participation in dopaminergic function (47). Transcriptional green fluorescent protein (GFP) fusions allow the eight DA neurons to be clearly visible in vivo under a fluorescent dissecting scope, and, as in vertebrates, the neurotoxicants 6-hydroxy dopamine (6-OHDA), 1-methyl-4-phenylpyridinium, and rotenone can confer DA neurodegeneration (48, 49). Expression of human α-synuclein in C. elegans also confers DA neurodegeneration, aggregate formation, movement deficits, disruption of vesicle docking, and significant changes in gene expression of molecular pathways associated with the mitochondria and proteasome (5052). Overexpression or mutations in other PD-associated genes also affect whole animal or DA neuron vulnerability (46, 53, 54).

In this study we describe a novel in vivo model for manganism. We show that a brief sub-lethal exposure of Mn2+ to C. elegans results in increases in ROS production and glutathione concentrations, a decrease in mitochondria membrane potential and oxygen consumption, and DA neurodegeneration. Mn2+ exposure also amplifies α-synuclein-induced DA neuronal death. DA neuron vulnerability to Mn2+ is partially dependent on the expression of DMT-1 homologue SMF-1 in DA neurons, because knockdown or deletion of the putative transporter partially protects against neuronal death. SMF-2, another DMT-1 homologue, is also expressed in DA neurons and contributes to the sensitivity to 6-OHDA, because knockdown or deletion of the protein partially protects against the DA cell death. These results suggest that the DMT-1 contributes to Mn2+-induced DA neuron vulnerability in manganism and PD.

EXPERIMENTAL PROCEDURES

C. elegans Strains and Maintenance

The following strains were obtained from the Caenorhabditis elegans Genetics Center: wild-type Bristol N2, IG6 smf-1(eh5) X, VC171 smf-2(gk133) X, and RB1074 smf-3(ok1035) IV. The Pdat1::GFP strain is an integrated, transgenic line expressing GFP from behind the dat-1 promoter and has been previously described (49, 50). This strain, now called BY250, was crossed into the mutant smf-1–3 backgrounds and followed by PCR using genomic DNA and the following primers: smf-1-F, GAATTTTGCTTTGGCGTGTT; smf-1-R, TCAGTTTGGCACCACGTTAG; smf-2-F, CGGCTCCAAAAATGGAAATA; smf-2-R, GGGAAATCAGGTAAAAATGTGC smf-3F, TTCAGCTTGTCAAGGGCTTT; and smf-3-R, CTTCCATTGGGGAAGTTTGA. The resulting strains were generated: RJ907 (Pdat-1::GFP; smf-1(eh5)), RJ905 (Pdat-1::GFP; smf-2(gk133)), and RJ906 (Pdat-1::GFP; smf-3(ok1035)). Animals expressing human WT α-synuclein behind the dat-1 promoter have previously been described (now called BY273 (Pdat-1::GFP; Pdat-1::WTα-synuclein). RJ928 is a genetic cross between BY250 and the RNA-mediated interference (RNAi)-sensitive NL2099 rrf-3(pk1426) nematodes. C. elegans strains were cultured on bacterial lawns of either OP-50 or NA-22 on NGM or 8P plates, respectively, at 20 °C according to standard methods (55, 56).

RNA Extraction and cDNA Synthesis

Total RNA was isolated from a synchronized C. elegans population using TRIzol reagent largely as described previously with minor modifications (57). Briefly, worm pellets after treatment with either MnCl2 or 6-OHDA were resuspended in TRIzol (1 ml/100 μl of compact worm pellet). Protein and lipid impurities were separated from nucleic acids using chloroform, and RNA was precipitated with isopropyl alcohol. The RNA pellet was washed with 75% ethanol, air-dried, dissolved in RNase-free water, and stored at −80 °C until used. RNA concentrations were measured using an ND-1000 spectrophotometer (Nanodrop Technology, Wilmington, DE). One microgram of total RNA was reverse-transcribed to cDNA using oligo(dT) (IDT DNA, Coralville, IA), and reverse transcriptase (Bio Rad), following the manufacturer's instructions (cDNA synthesis kit, Bio-Rad). The cDNA was purified using Microcon YM30 filters (Millipore Corp., Bedford, MA) and measured using an ND-1000 spectrophotometer.

qPCR Measurements

Gene specific primers were designed using Primer3 software, and the primers were designed to be exon spanning to avoid amplification of contaminating genomic DNA. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was selected as the housekeeping gene because its expression does not change as a result of MnCl2 or 6-OHDA treatment. The following primers were used to determine changes in gene expression of smf-1, smf-2, or smf-3 following Mn2+ exposure: smf-1 F, GTGGGTTTTGCTCTCAGCTC; smf-1 R, TGGCAATTGCTGTTCCAATA; smf-2 F, GCACTGGTTGGCTGATTTTT; smf-2 R, GGAGCATCCAGTTCCAGTGT; smf-3 F, GGAGTGCGAAAGTTTGAAGC; smf-3 R, TTGACAAGTGCCGAGTGAAG; GAPDH F, GAAACTGCTTCAACGCATCA; and GAPDH R, CCTTGGCGACAAGAAGGTAG. Real-time reaction was performed using 2× SYBR Green PCR master mix, using the ABI Prism 7500 sequence detection system (Applied Biosystems, Warrington, UK). Gene expression studies were performed in triplicate, and the formation of a single PCR product was confirmed using dissociation curves. Negative controls with the primers consisted of all of the components of PCR mix except cDNA. Relative -fold change in gene expression for each gene was calculated using normalized CT values (the cycle number at which the fluorescence passes the threshold).

Toxicant Exposures

Synchronized L1 stage worms were obtained by hypochlorite treatment of gravid adults followed by incubation of the embryos in M9 buffer for 18 h and washed at least 3× in dH2O using standard protocols (49, 58). L1 stage worms (10 worms/μl) were incubated with dH2O ± 50 mm manganese chloride (MnCl2, Fisher Scientific, Fair Lawn, NJ), or 1% DMSO ± 5 mm 6-OHDA (Sigma-Aldrich, as previously described (58)) for 30 min at room temperature (∼22 °C) with gentle mixing every 10 min. The light-sensitive 6-OHDA exposures were also performed in the dark. Following treatments, the worms were placed onto NGM/OP-50 plates and allowed to recover for 72 h at 20 °C. After recovery, 50–60 worms were immobilized on 2% agarose pads with 2% sodium azide and were scored for DA neurodegeneration under a fluorescence microscope (Leica MZ 16FA, Switzerland). Worms were scored positive for DA neuron degeneration when GFP in any part of the four cephalic dendrites (CEPs, which run from the nerve ring to tip of the nose) was absent (49). Each of the experiments was performed at least in triplicate, and the results are reported as means ± S.E. Osmotic control for MnCl2 studies was treated with 75 mm potassium gluconate (Sigma-Aldrich), whereas controls were treated with 1% DMSO for 6-OHDA experiments.

GSH Analysis

Total glutathione levels were determined using the ApoGSH glutathione detection kit (BioVision, Palo Alto, CA) following the manufacturer's instructions with slight modifications. Briefly, synchronized L1 stage worms were exposed to 50 mm MnCl2 and allowed to recover on NGM plates for 4 h at 20 °C. The worms were removed from the plates, and bacteria was removed from worms by three repeated washes and subsequent centrifugation. The worm pellet was homogenized by sonication, and the lysate was centrifuged at 14,000 rpm for 10 min at 4 °C. The supernatant was used for measuring total protein content and GSH levels. Monochlorobimane dye in the reaction forms adducts with GSH exclusively and fluoresces, whereas the unbound dye does not fluoresce. The intensity of the dye was measured at excitation and emission wavelengths of 380 and 460 nm, respectively. For each treatment group, at least three independent samples were prepared.

ROS Analysis

Total ROS formation was evaluated in the whole worm using 2,7-dichlorodihydrofluorescein diacetate (H2-DCF-DA). ROS oxidize the dye to the fluorescent 2,7-dichlorofluorescein, and the level of fluorescence corresponds to ROS cellular levels. ROS levels were determined following previously established protocols with slight modifications (59, 60). Briefly, synchronized L1 worms were exposed to MnCl2 as described above, and washed 3× with water. The animals were resuspended in M9 at a concentration of 50,000 worms/ml, and 50 μl of the suspension was incubated in 50 μl of freshly prepared 100 μm H2-DCF-DA in four replicates in a 96-well plate. Control wells included worms from each treatment without H2-DCF-DA or wells containing H2-DCF-DA without worms. The basal fluorescent signal from each well was measured at excitation and emission wavelengths of 485 and 520 nm, respectively, using a spectrophotometer (Tecan Spectrafluor Plus). Following the addition of the worms, plates were incubated on a shaker at room temperature for 1 h and were measured under earlier conditions. Fluorescence values from the control wells were subtracted from the corresponding signal value of each well after the final measurement. All assays were performed in triplicates.

Mitochondrial Membrane Potential Analysis

Mitochondrial membrane potential was measured using the lipophilic cationic dye tetramethyl rhodamine ethyl ester (TMRE, Sigma) as previously described (61, 62). Following exposure to 50 mm MnCl2, L1 stage worms were allowed to recover on NGM plates containing 0.1 μm TMRE for 48 h. The fluorescent images of the head region of each animal (from tip of nose to posterior end of terminal bulb) was captured using a Leica MZ 16FA fluorescence microscope, and the amount of dye accumulated was quantified using Image Pro Plus v6.2 software (Media Cybernetics, MD). The membrane potential of at least 20 live animals was evaluated in triplicate for each experimental condition.

Oxygen Consumption Analysis

Oxygen consumption was measured using a Mitocell MT200 respirometer and an oxygen electrode (Strathkelvin Instruments Ltd.) as previously described (60, 63). L1s were exposed to Mn2+ and allowed to recover on NGM plates at 20 °C for 48 h. Animals were then washed 3× with water and resuspended at a concentration of 6000 worms/ml. 60-μl aliquots were then transferred into the oxygen meter chamber, and the respiration rate was measured at 20 °C for 10 min. At least three independent experiments were performed comprising of at least three replicates per treatment group.

Antibodies and Immunohistochemistry

Antibodies to amino acids 1–61 and 428–465 from the putative C. elegans proteins SMF-1 (WP:CE37261) and SMF-2 (WP:CE02825), respectively, were generated using Genomic Antibody Technology at Strategic Diagnostics Inc. (Newark, DE). Rabbit polyclonal antibodies were further purified at Strategic Diagnostics Inc. Primary C. elegans cultures were prepared as previously described, but with slight modifications (64). Briefly, gravid adult worms were lysed with the synchronization solution as described earlier, and the egg pellet was washed using egg buffer (118 mm NaCl, 48 mm KCl, 2 mm CaCl2, 2 mm MgCl2, 25 mm HEPES), and the eggs were separated from the debris using a 60% sucrose solution. Eggs were digested using 4 mg/ml chitinase (Sigma), and embryonic cells were dissociated using syringe aspiration. Embryonic cells were then resuspended in L-15 medium (containing 10% fetal bovine serum and 1% penicillin/streptomycin) and grown on polylysine-coated slides at 20 °C. Following growth for 72 h, cells were fixed in 4% paraformaldehyde, permeabilized in 0.5% Triton X-100, and blocked using 1% normal goat serum. The cells were then incubated with either SMF-1 or SMF-2 primary antibodies (1:5000) at 4 °C overnight (14 h), followed by incubation with Texas Red-conjugated goat anti-rabbit secondary antibodies (Invitrogen, 1:5000) at room temperature for 1 h. Images were captured using confocal microscopy (Zeiss LSM 510 microscope).

RNA Interference

RNAi-sensitive NL2099 rrf-3(pk1426) nematodes were crossed into BY250 (65), and the resulting mutant strain (RJ928) was confirmed with PCR. RNAi experiments were carried out on NGM plates containing 1 mm isopropyl 1-thio-β-d-galactopyranoside and 100 μg/ml ampicillin and seeded with HT115 (DE3), an RNase III-deficient Escherichia coli strain carrying L4440 vector with the gene fragment (smf-1 or smf-2) (GeneService, Source BioScience, PLC, Nottingham, UK) or empty vector (Addgene, Cambridge, MA) (66). Synchronized L1 stage RJ928 worms were transferred onto RNAi plates, and the feeding protocol was followed with slight modifications (67). 50–100 second generation gravid adults grown on RNAi bacteria were transferred to fresh RNAi media plates and allowed to lay eggs for 5 h. Adults were then removed from the plate. L1s hatched from the eggs (third generation) were exposed to Mn2+ or 6-OHDA as described above. The animals were allowed to recover on the RNAi plates for 72 h and evaluated as previously described (49).

RESULTS

Mn2+ Exposure Increases Oxidative Stress in C. elegans

To determine whether a brief exposure to Mn2+ may cause an increase in oxidative stress in C. elegans, we exposed young animals to 50 mm MnCl2 for 30 min and determined whole animal GSH and ROS levels and oxygen consumption. Mitochondrial membrane potential changes were also evaluated in the head. One of the more important defenses against oxidative stress is the production of GSH, which reduces peroxides through GSH peroxidase-catalyzed reactions (68). GSH production has been observed to initially increase following exposures to a number of oxidants, including manganese and the dopamine-related metabolite quinone (21, 69). A brief exposure of C. elegans to 50 mm Mn2+ results in approximately a 5-fold increase in GSH levels 4 h post-exposure (Fig. 1A). These results indicate that C. elegans is sensitive to a single high level exposure to Mn2+ and are consistent with GSH activation in response to higher free radical levels. To determine whether an acute exposure to Mn2+ may cause a greater accumulation of ROS relative to non-exposed animals, we determined whole animal ROS levels using the ROS-dependent fluorescent dye DCF. L1 animals were resuspended in water with and without the addition of Mn2+, and ROS levels were quantified 1 h later. We found that a brief exposure to Mn2+ caused a 2-fold increase in cellular ROS relative to non-Mn2+ exposed animals (Fig. 1B). These results are consistent with vertebrate studies that show that Mn2+ can increase cellular free radical production. A primary intracellular target of Mn2+ in vertebrates is mitochondria (1). Increases in ROS production can be due to Mn2+-induced inhibition of complex I and activation of the permeability transition pore, resulting in the inefficient reduction of the final electron receptor and loss of mitochondrial membrane potential. To determine whether Mn2+ exposure may disrupt the mitochondrial membrane potential in the head region of C. elegans, we exposed control and Mn2+-treated animals for 48 h to TMRE. TMRE is a mitochondrial-specific fluorescent dye whose rate of uptake is dependent on the mitochondria membrane potential (61). A single exposure to 50 mm Mn2+ resulted in a significant decrease in mitochondria membrane potential within the head relative to non-exposed nematodes (Fig. 1C). These results suggest that, as in vertebrate systems, Mn2+ may impair mitochondria function. To further explore whether Mn2+ may be toxic to mitochondria in C. elegans, we determined total cellular oxygen utilization following toxicant exposure. Reduction in cellular oxygen consumption has been correlated with dysfunctional mitochondria in vertebrates and C. elegans (63, 68). L1 animals were exposed to water either with or without Mn2+, allowed to recover on plates containing bacteria for 48 h, and the respiration rate was determined. The rate of oxygen consumption for the Mn2+-exposed worms was reduced greater than 2-fold relative to control, suggesting impaired mitochondrial function (Fig. 1D). The above results suggest that exposure of C. elegans to Mn2+ can confer significant oxidative stress and, as in vertebrate systems, is likely due to the accumulation of ROS and mitochondrial dysfunction.

FIGURE 1.

FIGURE 1.

Mn2+ exposure increases oxidative stress in C. elegans. Synchronized L1 nematodes were treated with ± 50 mm MnCl2 for 30 min then allowed to recover on NGM plates for 4 h, and total glutathione levels were evaluated (A). ROS levels were measured with or without Mn2+ treatment and incubation with DCF-DA for 60 min (B). Head mitochondrial membrane potential was determined following ± Mn2+ exposure and incubation with TMRE for 48 h. Head region images (from the nose to the posterior part of the terminal bulb) were captured using a Leica MZ 16FA fluorescence microscope, and fluorescent intensity of the dye was determined using Image Pro Plus v6.2 software (C). Oxygen consumption rate was measured following ± Mn2+ treatment using a Mitocell MT200 and Strathkelvin oxygen electrode (D). Shown are mean values ± S.E. of three individual replicates. p values were calculated using t test analysis. *, p ≤ 0.03.

Exposure to Sub-lethal Concentrations of Mn2+ Confers DA Neurodegeneration

The DA neurons in vertebrates are particularly sensitive to oxidative stress and heavy metals, including Mn2+, and DA neurodegeneration contributes to the behavioral phenotypes associated with manganism and PD. We previously generated transgenic worms that express GFP in the eight dopamine neurons in the hermaphrodite (49). These neurons are clearly visible under a fluorescent dissecting scope. We also demonstrated that a brief exposure of the animals to 6-OHDA results in a significant loss of DA neurons within the head (49). To determine whether exposure to Mn2+ may also cause DA neurodegeneration, we exposed C. elegans in liquid suspension to various concentrations of toxicant ranging from 0 to 250 mm for 30 min and transferred the animals to agar plates. We found that a brief exposure to the Mn2+ caused a significant loss of DA neurons within 72 h at all concentrations tested, and ∼20% of the animals display DA neuron degeneration after exposure to 50 mm MnCl2 (Fig. 2, C and E). This brief exposure does not result in any apparent long term changes in whole animal morphology or behavior, which suggests there is not large scale cellular dysfunction or death. The Mn2+-induced DA neurodegeneration that we observed is similar to our prior studies in which we characterized the 6-OHDA-induced DA neurodegeneration by loss of dendritic GFP and loss of neuronal integrity by electron microscopy (49). In these studies, only the CEP processes that cannot be visually followed from the cell body to the tip of the nose are considered to have degeneration (49). Of those animals that demonstrate the neurodegeneration, on average we find one neuron (and sometimes more) that shows significant dendritic loss. We also observed other signs of DA neuron pathology such as the formation of neuronal blebs or a decrease in GFP intensity, even in animals that do not have an apparent loss of a dendrite, suggesting that there could be greater DA neuronal pathology than determined by loss of cellular integrity. To further evaluate the DA neuronal damage, we utilized high performance liquid chromatography analysis coupled to an electrochemical detection system to evaluate DA levels in Mn2+-exposed worms relative to non-Mn2+-exposed animals. A brief 30-min exposure to 50 mm Mn2+ followed by incubation on media growth plates at 20 °C for 48 h resulted in a loss of DA of ∼60% in Mn2+-exposed worms relatively to control animals (control worms = 33.15 ± 6.6 fmol/mg of wet weight, n = 6; Mn2+-exposed worms = 13.20 ± 0.8 fmol/mg of wet weight, n = 3). The decrease in DA concentration is consistent with DA neuronal loss, because the DA neurons are the only cells that generate DA in C. elegans (47). Taken together, these results indicate that an acute Mn2+ exposure can cause degeneration of the C. elegans DA neurons.

FIGURE 2.

FIGURE 2.

Mn2+ confers DA neuron degeneration in WT and human α-synuclein-expressing nematodes. A, GFP-expressing DA neurons (CEPs) within the head of a control worm exposed to water. Morphological changes were also not evident when exposed to the iso-osmotic solution of 75 mm potassium d-gluconate for the 50 mm exposures (data not shown). B, differential interference contrast image of the corresponding control animal. C, nematodes exposed to 50 mm MnCl2 for 30 min and evaluated 72 h later; image chosen emphasizes significant loss of CEP cell bodies and dendrites. D, differential interference contrast image of the corresponding worms in C. E, quantitation of DA neuron integrity in WT animals or human α-synuclein expressing animals (F) following exposure to water or Mn2+. Animals (≥50 worms/condition) were exposed to various concentrations of MnCl2, and the GFP expression pattern in the CEP was examined 72 h later (see “Experimental Methods”). Anterior of the animal is to the left. Scale bar = 35 μm. Shown are mean values ± S.E. of at least three individual replicates. p values were calculated using t test analysis. Asterisk indicates p = 0.03 for all comparisons compared with controls (0.0 mm Mn2+).

Mn2+ Exposure Amplifies α-Synuclein-induced DA Neuronal Death

Mn2+ causes an increase in α-synuclein aggregation and fibrillation in vitro and in vivo, suggesting that Mn2+ may interact synergistically with α-synuclein to cause DA neuron dysfunction and pathology (30, 70). We have previously generated transgenic C. elegans strains expressing human α-synuclein in DA neurons and find that WT and A53T α-synuclein expression confers DA neurodegeneration and the formation of inclusion-type bodies (50). To determine whether Mn2+ may amplify the toxicity of α-synuclein-induced DA neuronal death in vivo, we briefly exposed nematodes expressing human WT α-synuclein to 50 mm Mn2+, and found a small, yet significant increase in DA neuronal death (Fig. 2F). These results are consistent with vertebrate studies that suggest that Mn2+ can amplify the toxicity conferred by α-synuclein and may exacerbate the α-synuclein-associated DA neuron dysfunction in PD and manganism.

Expression of the Putative DMT-1 Transcripts smf-1, smf-2 and smf-3 Are Modulated by Mn2+ Exposure

A primary mechanism for entry of Mn2+ into vertebrate cells is through divalent metal transporter, DMT-1 (38). A BLAST search with a human homologue of DMT-1 and a sequence alignment of the results using ClustalW2 suggest that C. elegans has three putative homologues to DMT-1: SMF-1–3 (percent similarity from 72 to 76%, with percent amino acid identity between 55 and 58%) (Fig. 3) (71, 72). The putative transporters are predicted to have 12 transmembrane domains and, consistent with vertebrates, a conserved consensus transport sequence located between transmembrane domains eight and nine (73). We hypothesized that, because Mn2+ confers oxidative stress and DA neuronal death, the Mn2+ transporters responsible for cellular uptake and storage may be tightly regulated. If cellular Mn2+ is tightly regulated in C. elegans, we further hypothesized that an acute sub-lethal exposure to Mn2+ may cause a significant change in gene expression of the putative transporters. We utilized quantitative PCR to determine gene expression levels in control and Mn2+-exposed worms. Young nematodes exposed to 50 mm MnCl2 for 30 min showed a significant and rapid reduction of mRNA levels, ranging from ∼1.8- to 5.0-fold change (Fig. 4) (supplemental Fig. S1). These results indicate that the gene expression is highly sensitive to environmental Mn2+ and suggest that the down-regulation of the putative transporters could be an attempt to limit cellular or cytoplasmic Mn2+ concentrations and toxicity.

FIGURE 3.

FIGURE 3.

Sequence alignment of putative C. elegans DMT homologues with yeast and mammalian DMTs. The sequences of human DMT (GenBankTM accession number NP_000608), murine Nramp2 (GenBankTM number L33415), yeast SMF1P (GenBankTM accession number NC_001147), C. elegans SMF-1 (GenBankTM accession number AAC46569), C. elegans SMF-2 (GenBankTM accession number AAC46568) and C. elegans SMF-3 (GenBankTM accession number AAL27264) were aligned using the ClustalW2 program following an NCBI BLAST search. The twelve putative transmembrane regions are highlighted in black; the arrow above the sequence indicates the orientation relative to the membrane, i.e. right-directed arrowhead = N-terminal to C-terminal, extracellular to intracellular. Consensus transport sequence located between transmembrane domains eight and nine are highlighted in green. The red font in the sequence represents hydrophobic amino acids, whereas blue represents acidic, magenta represents basic, green represents hydroxyl, and gray represents other types of amino acids. The asterisk indicates amino acids in that column are identical, colons represent conserved substitutions (same color group), and periods represent semi-conserved substitution (similar shapes). A BLAST search with the human homologue of DMT-1, and a sequence alignment of the results using ClustalW2 suggests that C. elegans has three putative homologues, SMF-1–3 (percent similarity from 69% to 76%, with percent amino acid identity between 53 and 58%).

FIGURE 4.

FIGURE 4.

Expression of smf-1, smf-2, and smf-3 transcripts are modulated by exposure to Mn2+. L1 animals were exposed to 50 mm MnCl2 for 30 min, mRNA-extracted, and reverse-transcribed to cDNA. Relative gene expression changes of smf-1, smf-2, and smf-3 were quantitated using real-time PCR. The -fold change in gene expression relative to GAPDH was calculated for each gene following the ΔΔCT method. Shown are mean values for -fold change ± S.E. of three individual replicates. *, indicates p ≤ 0.02 between control and Mn2+-treated group ΔCT values.

SMF-1 and SMF-2 Are Expressed in DA Neurons

DMT-1 has recently been implicated in regulating Fe2+-mediated DA neuron cell death in vitro and in PD (44). The transporter is also expressed in humans in DA neurons in the substantia nigra, and three homologues are expressed in yeast (73, 74). In yeast, Smf1p and Smf2p appear to be regulated by Mn2+, while Smf3p may be regulated through a non-Mn2+ pathway (74). Each of the three putative homologues in C. elegans have primary and secondary sequence similarities characteristics with their yeast number counterparts, suggesting that the C. elegans SMF-1 or SMF-2 may be more likely to be involved in Mn2+ transport. To determine whether SMF-1 or SMF-2 is expressed in C. elegans DA neurons, we generated antibodies to both nematode proteins. To determine specificity of the antibodies and the role that the SMF proteins may play in Mn2+-mediated DA neurodegeneration, we crossed our Pdat-1::GFP transgenic animals (BY250) into C. elegans strains that contain either a mutation in SMF-1 (IG6 smf-1(eh5) X) or SMF-2 (VC171 smf-2(gk133) X) resulting in strains RJ907 and RJ905, respectively. The smf-1(eh5) mutation contains a 2063-bp deletion in smf-1 that results in a truncation of the protein beginning in transmembrane domain six. The mutation likely results in a null mutant, because the consensus transport sequence has been deleted. The smf-2(gk133) mutation contains a 448-bp deletion in the smf-2 gene and likely results in a non-functional protein, because the deletion spans the start codon and the first three transmembrane domains. The morphology of the DA neurons in animals containing mutations in either smf-1 or smf-2 appear identical to those of BY250 (data not shown), suggesting that these transporters do not play a significant role in maintaining DA neuron integrity. To determine whether the DA neurons express SMF-1 or SMF-2, we generated primary cultures from BY250 animals. GFP is strongly expressed in DA neurons both in vivo and in vitro (49, 75). We used affinity-purified anti-SMF-1 to evaluate cellular SMF-1 expression levels. SMF-1 immunoreactivity is observed in DA neurons, as well as other cell types (Fig. 5, A–D). No specific staining was observed in DA primary neurons or other cells from smf-1 mutant worms (Fig. 5, E–H). These results indicate that SMF-1 is expressed in DA neurons and that the antibody is likely specific for the putative transporter. As observed with SMF-1 immunofluorescence, SMF-2 is also expressed in DA neurons, as well as other cells, and the SMF-2 antibody did not immunoreact with other cells in the smf-2 mutant primary cultures (Fig. 6, A–H). Taken together, these results indicate that SMF-1 and SMF-2 proteins are expressed in DA neurons and that animals containing the deletions within SMF-1 or SMF-2 likely do not express the proteins in their respective mutant backgrounds.

FIGURE 5.

FIGURE 5.

SMF-1 is expressed in DA neurons. Primary C. elegans cultures expressing GFP in the DA neurons were generated with WT (A–D) or smf-1 mutants (E–H), and fixation was performed as described under “Experimental Procedures.” Primary cultures were incubated with SMF-1 primary antibodies followed by incubation with Texas Red-conjugated goat anti-rabbit secondary antibodies. Differential interference contrast images of A and E of WT and smf-1 mutant cultures, respectively, are shown. DA neurons from WT and smf-1 mutants expressing GFP driven by the dat-1 promoter B and F, respectively. SMF-1 colocalized with DA neurons in WT animals (C), but not in smf-1 mutants (G). D, overlay of B and C; H overlay of F and G. Images were observed under a Zeiss confocal microscope (Zeiss LSM 510). Scale bar represents 45 μm.

FIGURE 6.

FIGURE 6.

SMF-2 is expressed in DA neurons. Primary C. elegans cultures expressing GFP in the DA neurons were generated with WT (A–D) or smf-2 mutants (E–H), and fixation was performed as described under “Experimental Procedures.” Primary cultures were incubated with SMF-2 primary antibodies followed by incubation with Texas Red-conjugated goat anti-rabbit secondary antibodies. Differential interference contrast images of A and E of WT and smf-2 mutant cultures, respectively, are shown. DA neurons from WT (B) and smf-2 (F) mutants expressing GFP driven by the dat-1 promoter. SMF-2 colocalizes with DA neurons in WT animals (C), but not in smf-2 mutants (G). D, overlay of B and C; H, overlay of F and G. Images were observed under a Zeiss confocal microscope (Zeiss LSM 510). Scale bar represents 45 μm.

SMF-1 Contributes to Mn2+-induced DA Neurodegeneration

Vertebrate DMTs transport divalent cations into the cell or intracellular compartments and may play a role in the generation of Mn2+-induced oxidative stress (1, 76, 77). Because Mn2+ exposure can confer DA neurodegeneration, and SMF 1 and SMF 2 are expressed in DA neurons, we asked whether the putative transporters may contribute to Mn2+-induced DA neuron vulnerability. Nematodes were grown for two generations on RNAi bacteria to reduce expression of either smf-1 or smf-2 or both genes together. Reduction in mRNA levels of smf-1 or/and smf-2 was confirmed by quantitative PCR (data not shown). RNAi of either smf-1 or smf-2 is also specific and robust, because knockdown of either protein resulted in loss of immunoreactivity with its corresponding antibody while not affecting the expression of the orthologue (supplemental Figs. S2 and S3). L1 larvae were exposed to 50 mm MnCl2 for 30 min and allowed to recover on the RNAi bacteria for an additional 72 h, and DA neuronal morphology was evaluated. Animals in which smf-1 gene expression was reduced show 42% more resistance to Mn2+-induced DA neurodegeneration relative to WT animals (Fig. 7A). Furthermore, there was not a significant difference in Mn2+-induced DA neuronal death between WT animals and animals with a reduction in smf-2 expression. Animals with a reduction in expression of both genes also did not decrease DA neuron vulnerability relative to the smf-1 knockdown, suggesting that smf-2 does not compensate for the reduction in smf-1 expression. To determine whether a probable functional deletion in either gene can protect DA neurons against Mn2+ toxicity, we exposed the mutant animals to Mn2+ and evaluated the DA neuronal integrity 72 h later. Consistent with our RNAi studies, the smf-1 mutants were 40% more tolerant to Mn2+ relative to the WT animals (Fig. 7B). Furthermore, the likely functional deletion of SMF-2 did not decrease the vulnerability of DA neurons to Mn2+. To determine whether SMF-3 may contribute to Mn2+-induced DA neuronal death, we crossed the animals expressing GFP in the DA neurons with the likely smf-3 functional deletion mutant RB1074; this transporter is likely non-functional, because the C terminus has a deletion that includes ∼80% of the consensus transport sequence. DA neurons in animals containing the smf-3 mutation were not more resistant to Mn2+ relative to WT (Fig. 7B). Taken together, these results indicate that expression of SMF-1 increased DA neuron vulnerability to Mn2+, and neither SMF-2 nor SMF-3 contributed to the neurotoxicity.

FIGURE 7.

FIGURE 7.

SMF-1 contributes to Mn2+-induced DA neurodegeneration, and SMF-1 and SMF-2 contribute to 6-OHDA-induced DA neuronal death in C. elegans. Synchronized L1 WT and mutant smf-1 and smf-2 worms were exposed to either 50 mm MnCl2 or 5 mm 6-OHDAfor 30 min and allowed to recover on NGM plates at 20 °C for 72 h as described under “Experimental Procedures.” RNAi gene expression reduction (A) or deletion (B) of smf-1 confers partial protection against Mn2+-induced DA neurodegeneration. RNAi gene expression reduction (C) or deletion (D) of both smf-1 and smf-2 conferred partial protection against 6-OHDA-induced DA neurodegeneration. SMF-3 does not contribute significantly to Mn2+- or 6-OHDA-induced DA neuronal death (B and C). Shown are mean values ± S.E. of at least three individual replicates. p values were calculated using t test analysis. *, p ≤ 0.03 between WT and mutants or RNAi worms.

SMF-1 and SMF-2 Contribute to 6-OHDA-induced DA Neurodegeneration

DMT-1 has recently been shown to contribute to DA neuron vulnerability in PD and vertebrate models, likely through an Fe2+-dependent mechanism. To determine if SMF-1 or SMF-2 contributes to 6-OHDA-induced DA neuron degeneration in C. elegans, we knocked down gene expression of each of the genes as described above and exposed the animals for 30 min to 5 mm 6-OHDA as previously described (49, 58). Following a 72-h recovery, we found that animals that have reduced expression of smf-1 or smf-2 were 1.7 and 2.9 times more resistant to 6-OHDA-induced death than controls, respectively (Fig. 7C). Consistent with the RNAi studies, animals containing mutations within either SMF-1 or SMF-2 significantly protect DA neurons against the neurotoxicant (2.4- and 4.2-fold, respectively) (Fig. 7D). SMF-3 also does not appear to play a role in the toxicity, because deletion of the gene does not provide protection against 6-OHDA-induced cell death. These results indicate that both SMF-1 and SMF-2 play a role in 6-OHDA-induced DA neuronal death and provide further evidence that divalent cations contribute to PD-associated DA cell death.

DISCUSSION

Overexposure to Mn2+ can cause the neurological disorder Parkinsonism and has been implicated as an environmental toxicant that may contribute to the development of PD. Both disorders share a number of clinical and pathophysiological features that includes motor deficits, DA neuronal damage, and mitochondria dysfunction, which suggests that there may be overlapping modalities and molecular pathways that contribute to the pathologies. A difficulty in dissecting the molecular determinants in both disorders includes the cellular complexity of the vertebrate brain and the lack of facile in vivo genetic models to dissect the molecular mechanisms involved in Mn2+-induced DA neuron cell death. In this study, we describe a novel in vivo model for manganism and show that the C. elegans DA neurons degenerate following a brief exposure to Mn2+ (Fig. 2, A–E). We also show that SMF-1, a homologue of the vertebrate Mn2+ transporter DMT-1, is expressed in the DA neurons, and genetic knockdown or deletion of the transporter partially inhibits the neurodegeneration (Figs. 5 and 7). Considering the strong sequence similarities between SMF-1 and DMT-1, and the role SMF-1 plays in Mn2+-induced cell death, our studies suggest that SMF-1 contributes to Mn2+-induced DA neuron vulnerability by transporting the ion into the cell or into a Mn2+-sensitive intracellular compartment.

DMT-1 has recently been found to be elevated in PD patients relative to age-matched controls and may contribute to the excess Fe2+ found in the mesencephalon associated with PD (44). DMT-1 has also been proposed to contribute to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- and 6-OHDA-induced DA neuron toxicity in rodents and primates by increasing cellular Fe2+ levels and by providing a catalyst for the Fenton reaction or Haber-Weiss reaction, whose products include the highly reactive hydroxyl radical that causes protein denaturation, lipid peroxidation, and cellular death (44, 78). Our studies also show that SMF-2 is expressed in DA neurons, and expression of either SMF-1 or SMF-2 dramatically increases DA neuron sensitivity to 6-OHDA (Figs. 6 and 7). These results suggest that the transporters may be facilitating neuronal death by the Fe2+-catalyzed Fenton reaction. Mn2+ can also catalyze Fenton reactions, and SMF-1 could be contributing to the neurotoxicity as well through this molecular pathway (10, 79). Furthermore, Mn2+ exposure may increase expression of the transporters to allow greater Mn2+ influx, because Mn2+ has previously been shown to increase DMT-1 mRNA and protein expression in cultured choroidal epithelia (80). Although we find that an acute elevated exposure to Mn2+ decreases SMF mRNA levels immediately following the exposure (Fig. 4), examination of SMF-1 protein expression levels at later time points would provide insight into this mechanism.

SMF-1 or SMF-2 may also be involved directly or indirectly in the regulation of DA-associated proteins that could affect DA neuron vulnerability to the neurotoxicant. For example, Fe2+ regulation has been proposed to affect expression levels of DAT or tyrosine hydroxylase, the rate-limiting enzyme for dopamine (81). DAT transports 6-OHDA into DA neurons and has been proposed to play a role in DA neuron vulnerability to environmental toxicants (49, 82, 83). A reduction in DAT in the SMF mutant animals could result in lower quantities of toxicants entering the cell with a concomitant decrease in cell death. Tyrosine hydroxylase also requires Fe2+ as a cofactor, and a reduction in Fe2+ has been shown to decrease tyrosine hydroxylase and dopaminergic activity, which could result in decreases in susceptibility to DA neuronal insult (81, 84). Furthermore, DAT is also a target for Mn2+, and exposure to Mn2+ has been shown to increase DAT surface expression that could result in increases in neuronal vulnerability (85).

α-Synuclein, a presynaptic protein of largely unknown function, was the first human gene identified in which a mutation appears to cause the development of (familial) PD (32, 33). Multiplications of the normal allele suggest that the gene is also a risk factor for the much more common sporadic (idiopathic) form of the disease. In vitro studies indicate that Mn2+ causes an increase in aggregation and fibrillation of α-synuclein, and greater cell death in cells expressing DAT (30, 70). Recently, suppression of α-synuclein-induced toxicity has been demonstrated by expression of the yeast or C. elegans orthologue of the human ATP13A2 (PARK9) (31). PARK9, a P-type ATPase associated with causing familial PD with dementia, localizes to lysosomes, and likely transports Mn2+ away from the cytoplasm into the intracellular compartment (86). Our studies show that DA neurons in nematodes exposed to Mn2+ and expressing WT human α-synuclein have an increase in DA neuronal death relative to non-α-synuclein-expressing animals, consistent with vertebrate and cell culture studies (Fig. 2F). Furthermore, RNAi of smf-1 in α-synuclein-expressing RNAi-sensitive nematodes alleviates the greater Mn2+-induced DA neuronal death (data not shown), supporting the role of the transporter in the neurodegeneration. Abnormal Fe2+ and/or DA regulation as described above may also contribute to the α-synuclein-induced pathology (87, 88).

Acute Mn2+ exposure rapidly represses transcription of all three transporters, yet only SMF-1 appears to play a role in DA neuron sensitivity to Mn2+ (Figs. 4 and 7). The yeast Smf1p plays a significant role in cellular influx of Mn2+ largely when Mn2+ in the environment is limited (42). It is possible that SMF-1 protein expression levels in animals grown under normal laboratory conditions may also be higher relative to those grown in a Mn2+-rich environment. Our studies involved exposing animals to high Mn2+ following incubation in an M9 synchronization buffer or following growth on RNAi media plates that contain <0.2 and 2.0 nm Mn2+, respectively. Higher media Mn2+ concentrations may be more optimal for growth, considering an addition of up to 2 mm MnSO4 can increase the rate of C. elegans development and brood size (89).

Excess exposure to Mn2+ in mammals in vitro and in vivo can confer oxidative stress and mitochondria dysfunction. Our studies also suggest that Mn2+ recapitulates vertebrate models. Pharmacological and toxicological studies in C. elegans are often performed at compound concentrations 10-fold or greater due to the difficulty of compounds crossing the moderately impermeable cuticle; intracellular concentrations of solutes, and Ki's and Km's of proteins or compounds with their respective molecular targets though are often similar to those found in other eukaryotes (45, 47, 90). A single sublethal 50 mm Mn2+ exposure in the nematode also confers oxidative stress and mitochondria dysfunction as determined by increases in glutathione production and ROS and decreases in oxygen consumption and head mitochondria membrane potential (Fig. 1). Also, our initial studies indicate that C. elegans tissue harvested from agar plates contain ∼48 nm Mn2+.3 Following a 30-min exposure to 50 mm Mn2+ and a 30-h recovery period (before DA neuron cell death is apparent), Mn2+ tissue concentrations are ∼7 μm. Considering that non-Mn2+ challenged vertebrate tissue generally contains <4 μm Mn2+, our studies suggest that C. elegans cellular and mitochondria Mn2+ sensitivities are similar to vertebrate systems (91).

In summary, our findings describe a novel genetic model for manganism. We show that Mn2+ causes oxidative stress, mitochondrial dysfunction, and DA neuron cell death in C. elegans and that the DMT-1 homologue SMF-1 significantly contributes to the cell death. We also show that SMF-1 and SMF-2 localize to the DA neurons and that knock down or deletion of either gene inhibits 6-OHDA-induced DA neurodegeneration. The development of this genetic model should facilitate the identification of molecules and pathways involved in PD-associated and Mn2+-induced DA neuron dysfunction and death.

Acknowledgments

We gratefully appreciate the technical assistance of Michelle Fullard, Marketa Marvanova, Shaoyu Zhou, and Randy Hunter. We are thankful to Eric A. Engleman and Gabriel Filippelli for assistance with determining C. elegans DA and Mn2+ concentrations, respectively. We also appreciate early discussions with Michael Aschner. Some of the strains were provided by the Caenorhabditis Genetics Center, which is supported by the National Institutes of Health Center for Research Resources.

*

This work was supported, in whole or in part, by National Institutes of Health Grants R011ES014459 and R01ES010563 from NIEHS. This work was also supported by Grant W81XWH-05-1-0239 from the Dept. of Defense Manganese Health Research Program (to R. N.).

Inline graphic

The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1–S3.

3

R. Settivari, G. Filippelli, and R. Nass, unpublished observation.

2
The abbreviations used are:
PD
Parkinson disease
DA
dopamine
DMT-1
divalent metal transporter-1
ROS
reactive oxygen species
GFP
green fluorescent protein
6-OHDA
6-hydroxy dopamine
RNAi
RNA interference
CEP
cephalic dendrite
H2-DCF-DA
2,7-dichlorodihydrofluorescein diacetate
TMRE
tetramethyl rhodamine ethyl ester
WT
wild type
GAPDH
glyceraldehyde-3-phosphate dehydrogenase
NGM
nematode growth medium
DAT
dopamine transporter.

REFERENCES

  • 1.Burton N. C., Guilarte T. R. (2009) Environ. Health Perspect. 117, 325–332 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Takeda A. (2003) Brain Res. Brain Res. Rev. 41, 79–87 [DOI] [PubMed] [Google Scholar]
  • 3.Aschner J. L., Aschner M. (2005) Mol. Aspects Med. 26, 353–362 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Hurley L. S., Woolley D. E., Rosenthal F., Timiras P. S. (1963) Am. J. Physiol. 204, 493–496 [DOI] [PubMed] [Google Scholar]
  • 5.Abdel-Naby S., Hassanein M. (1965) J. Neurol. Neurosurg. Psychiatry 28, 282–288 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Witholt R., Gwiazda R. H., Smith D. R. (2000) Neurotoxicol. Teratol. 22, 851–861 [DOI] [PubMed] [Google Scholar]
  • 7.Chia S. E., Foo S. C., Gan S. L., Jeyaratnam J., Tian C. S. (1993) Scand. J. Work Environ. Health 19, 264–270 [DOI] [PubMed] [Google Scholar]
  • 8.Rodier J. (1955) Br. J. Ind. Med. 12, 21–35 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Jiang Y. M., Mo X. A., Du F. Q., Fu X., Zhu X. Y., Gao H. Y., Xie J. L., Liao F. L., Pira E., Zheng W. (2006) J. Occup. Environ. Med. 48, 644–649 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Crossgrove J., Zheng W. (2004) NMR Biomed. 17, 544–553 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Racette B. A., McGee-Minnich L., Moerlein S. M., Mink J. W., Videen T. O., Perlmutter J. S. (2001) Neurology 56, 8–13 [DOI] [PubMed] [Google Scholar]
  • 12.Fishman B. E., McGinley P. A., Gianutsos G. (1987) Toxicology 45, 193–201 [DOI] [PubMed] [Google Scholar]
  • 13.Thiruchelvam M., McCormack A., Richfield E. K., Baggs R. B., Tank A. W., Di Monte D. A., Cory-Slechta D. A. (2003) Eur. J. Neurosci. 18, 589–600 [DOI] [PubMed] [Google Scholar]
  • 14.Domico L. M., Zeevalk G. D., Bernard L. P., Cooper K. R. (2006) Neurotoxicology 27, 816–825 [DOI] [PubMed] [Google Scholar]
  • 15.de Bie R. M., Gladstone R. M., Strafella A. P., Ko J. H., Lang A. E. (2007) Arch. Neurol. 64, 886–889 [DOI] [PubMed] [Google Scholar]
  • 16.Holzgraefe M., Poser W., Kijewski H., Beuche W. (1986) J. Toxicol. Clin. Toxicol. 24, 235–244 [DOI] [PubMed] [Google Scholar]
  • 17.Fahn S. (2008) in Parkinson's Disease: Molecular and Therapeutic Insights from Model Systems ( Nass R., Przedborski S. eds) pp.3– 8, Elsevier Academic Press, New York [Google Scholar]
  • 18.Gorell J. M., Johnson C. C., Rybicki B. A., Peterson E. L., Kortsha G. X., Brown G. G., Richardson R. J. (1999) Neurotoxicology 20, 239–247 [PubMed] [Google Scholar]
  • 19.Zayed J., Ducic S., Campanella G., Panisset J. C., André P., Masson H., Roy M. (1990) Can. J. Neurol. Sci. 17, 286–291 [PubMed] [Google Scholar]
  • 20.Barbeau A. (1984) Neurotoxicology 5, 13–35 [PubMed] [Google Scholar]
  • 21.Desole M. S., Miele M., Esposito G., Migheli R., Fresu L., De Natale G., Miele E. (1994) Arch. Toxicol. 68, 566–570 [DOI] [PubMed] [Google Scholar]
  • 22.Oestreicher E., Sengstock G. J., Riederer P., Olanow C. W., Dunn A. J., Arendash G. W. (1994) Brain Res. 660, 8–18 [DOI] [PubMed] [Google Scholar]
  • 23.Dobson A. W., Weber S., Dorman D. C., Lash L. K., Erikson K. M., Aschner M. (2003) Biol. Trace Elem. Res. 93, 113–126 [DOI] [PubMed] [Google Scholar]
  • 24.Parenti M., Rusconi L., Cappabianca V., Parati E. A., Groppetti A. (1988) Brain Res. 473, 236–240 [DOI] [PubMed] [Google Scholar]
  • 25.Erikson K. M., Dorman D. C., Lash L. H., Aschner M. (2007) Toxicol. Sci. 97, 459–466 [DOI] [PubMed] [Google Scholar]
  • 26.Migheli R., Godani C., Sciola L., Delogu M. R., Serra P. A., Zangani D., De Natale G., Miele E., Desole M. S. (1999) J. Neurochem. 73, 1155–1163 [DOI] [PubMed] [Google Scholar]
  • 27.Zhao F., Cai T., Liu M., Zheng G., Luo W., Chen J. (2009) Toxicol. Sci. 107, 156–164 [DOI] [PubMed] [Google Scholar]
  • 28.Higashi Y., Asanuma M., Miyazaki I., Hattori N., Mizuno Y., Ogawa N. (2004) J. Neurochem. 89, 1490–1497 [DOI] [PubMed] [Google Scholar]
  • 29.Tomás-Camardiel M., Herrera A. J., Venero J. L., Cruz Sánchez-Hidalgo M., Cano J., Machado A. (2002) Brain Res. Mol. Brain Res. 103, 116–129 [DOI] [PubMed] [Google Scholar]
  • 30.Uversky V. N., Li J., Fink A. L. (2001) J. Biol. Chem. 276, 44284–44296 [DOI] [PubMed] [Google Scholar]
  • 31.Gitler A. D., Chesi A., Geddie M. L., Strathearn K. E., Hamamichi S., Hill K. J., Caldwell K. A., Caldwell G. A., Cooper A. A., Rochet J. C., Lindquist S. (2009) Nat. Genet. 41, 308–315 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Polymeropoulos M. H., Lavedan C., Leroy E., Ide S. E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E. S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W. G., Lazzarini A. M., Duvoisin R. C., Di Iorio G., Golbe L. I., Nussbaum R. L. (1997) Science 276, 2045–2047 [DOI] [PubMed] [Google Scholar]
  • 33.Cookson M. R. (2009) Mol. Neurodegener. 4, 9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Chen J. Y., Tsao G. C., Zhao Q., Zheng W. (2001) Toxicol. Appl. Pharmacol. 175, 160–168 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Stredrick D. L., Stokes A. H., Worst T. J., Freeman W. M., Johnson E. A., Lash L. H., Aschner M., Vrana K. E. (2004) Neurotoxicology 25, 543–553 [DOI] [PubMed] [Google Scholar]
  • 36.HaMai D., Bondy S. C. (2004) Ann. N.Y. Acad. Sci. 1012, 129–141 [DOI] [PubMed] [Google Scholar]
  • 37.Garrick M. D., Dolan K. G., Horbinski C., Ghio A. J., Higgins D., Porubcin M., Moore E. G., Hainsworth L. N., Umbreit J. N., Conrad M. E., Feng L., Lis A., Roth J. A., Singleton S., Garrick L. M. (2003) Biometals 16, 41–54 [DOI] [PubMed] [Google Scholar]
  • 38.Papp-Wallace K. M., Maguire M. E. (2006) Annu. Rev. Microbiol. 60, 187–209 [DOI] [PubMed] [Google Scholar]
  • 39.Supek F., Supekova L., Nelson H., Nelson N. (1996) Proc. Natl. Acad. Sci. U.S.A. 93, 5105–5110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Liu X. F., Culotta V. C. (1999) J. Biol. Chem. 274, 4863–4868 [DOI] [PubMed] [Google Scholar]
  • 41.Luk E. E., Culotta V. C. (2001) J. Biol. Chem. 276, 47556–47562 [DOI] [PubMed] [Google Scholar]
  • 42.Culotta V. C., Yang M., Hall M. D. (2005) Eukaryot. Cell 4, 1159–1165 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Hubert N., Hentze M. W. (2002) Proc. Natl. Acad. Sci. U.S.A. 99, 12345–12350 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Salazar J., Mena N., Hunot S., Prigent A., Alvarez-Fischer D., Arredondo M., Duyckaerts C., Sazdovitch V., Zhao L., Garrick L. M., Nuñez M. T., Garrick M. D., Raisman-Vozari R., Hirsch E. C. (2008) Proc. Natl. Acad. Sci. U.S.A. 105, 18578–18583 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Nass R., Merchant K. M., Ryan T. (2008) Mol. Interv. 8, 284–293 [DOI] [PubMed] [Google Scholar]
  • 46.Nass R., Settivari R. S. (2008) in Parkinson's Disease: Molecular and Therapeutic Insights from Model Systems ( Nass R., Przedborski S. eds) pp.347– 360, Elsevier Academic Press, New York [Google Scholar]
  • 47.Nass R., Blakely R. D. (2003) Annu. Rev. Pharmacol. Toxicol. 43, 521–544 [DOI] [PubMed] [Google Scholar]
  • 48.Nass R., Miller D. M., Blakely R. D. (2001) Parkinsonism Relat. Disord. 7, 185–191 [DOI] [PubMed] [Google Scholar]
  • 49.Nass R., Hall D. H., Miller D. M., 3rd, Blakely R. D. (2002) Proc. Natl. Acad. Sci. U.S.A. 99, 3264–3269 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Lakso M., Vartiainen S., Moilanen A. M., Sirviö J., Thomas J. H., Nass R., Blakely R. D., Wong G. (2003) J. Neurochem. 86, 165–172 [DOI] [PubMed] [Google Scholar]
  • 51.Cooper A. A., Gitler A. D., Cashikar A., Haynes C. M., Hill K. J., Bhullar B., Liu K., Xu K., Strathearn K. E., Liu F., Cao S., Caldwell K. A., Caldwell G. A., Marsischky G., Kolodner R. D., Labaer J., Rochet J. C., Bonini N. M., Lindquist S. (2006) Science 313, 324–328 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Vartiainen S., Pehkonen P., Lakso M., Nass R., Wong G. (2006) Neurobiol. Dis. 22, 477–486 [DOI] [PubMed] [Google Scholar]
  • 53.Ved R., Saha S., Westlund B., Perier C., Burnam L., Sluder A., Hoener M., Rodrigues C. M., Alfonso A., Steer C., Liu L., Przedborski S., Wolozin B. (2005) J. Biol. Chem. 280, 42655–42668 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Springer W., Hoppe T., Schmidt E., Baumeister R. (2005) Hum. Mol. Genet. 14, 3407–3423 [DOI] [PubMed] [Google Scholar]
  • 55.Brenner S. (1974) Genetics 77, 71–94 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Hope I. (1999) C. elegans: A Practical Approach, pp. 1– 15,Oxford University Press, New York [Google Scholar]
  • 57.Novillo A., Won S. J., Li C., Callard I. P. (2005) Integr. Comp. Biol. 45, 61–71 [DOI] [PubMed] [Google Scholar]
  • 58.Nass R., Hamza I. (2007) Curr. Protoc. Toxicol. 1.9.1– 1.9.18 [DOI] [PubMed] [Google Scholar]
  • 59.Kampkötter A., Pielarski T., Rohrig R., Timpel C., Chovolou Y., Wätjen W., Kahl R. (2007) Pharmacol. Res. 55, 139–147 [DOI] [PubMed] [Google Scholar]
  • 60.Schulz T. J., Zarse K., Voigt A., Urban N., Birringer M., Ristow M. (2007) Cell Metab. 6, 280–293 [DOI] [PubMed] [Google Scholar]
  • 61.Yoneda T., Benedetti C., Urano F., Clark S. G., Harding H. P., Ron D. (2004) J. Cell Sci. 117, 4055–4066 [DOI] [PubMed] [Google Scholar]
  • 62.Ehrenberg B., Montana V., Wei M. D., Wuskell J. P., Loew L. M. (1988) Biophys. J. 53, 785–794 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Zarse K., Schulz T. J., Birringer M., Ristow M. (2007) FASEB J. 21, 1271–1275 [DOI] [PubMed] [Google Scholar]
  • 64.Bianchi L., Driscoll M. (2006) WormBook, The C. elegans Research Community (on-line) [Google Scholar]
  • 65.Simmer F., Tijsterman M., Parrish S., Koushika S. P., Nonet M. L., Fire A., Ahringer J., Plasterk R. H. (2002) Curr. Biol. 12, 1317–1319 [DOI] [PubMed] [Google Scholar]
  • 66.Timmons L., Fire A. (1998) Nature 395, 854. [DOI] [PubMed] [Google Scholar]
  • 67.Kamath R. S., Ahringer J. (2003) Methods 30, 313–321 [DOI] [PubMed] [Google Scholar]
  • 68.Schulz J. B., Lindenau J., Seyfried J., Dichgans J. (2000) Eur. J. Biochem. 267, 4904–4911 [DOI] [PubMed] [Google Scholar]
  • 69.Shi M. M., Kugelman A., Iwamoto T., Tian L., Forman H. J. (1994) J. Biol. Chem. 269, 26512–26517 [PubMed] [Google Scholar]
  • 70.Pifl C., Khorchide M., Kattinger A., Reither H., Hardy J., Hornykiewicz O. (2004) Neurosci. Lett. 354, 34–37 [DOI] [PubMed] [Google Scholar]
  • 71.Altschul S. F. (1991) J. Mol. Biol. 219, 555–565 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Larkin M. A., Blackshields G., Brown N. P., Chenna R., McGettigan P. A., McWilliam H., Valentin F., Wallace I. M., Wilm A., Lopez R., Thompson J. D., Gibson T. J., Higgins D. G. (2007) Bioinformatics 23, 2947–2948 [DOI] [PubMed] [Google Scholar]
  • 73.Cellier M., Privé G., Belouchi A., Kwan T., Rodrigues V., Chia W., Gros P. (1995) Proc. Natl. Acad. Sci. U.S.A. 92, 10089–10093 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Portnoy M. E., Liu X. F., Culotta V. C. (2000) Mol. Cell. Biol. 20, 7893–7902 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Carvelli L., McDonald P. W., Blakely R. D., Defelice L. J. (2004) Proc. Natl. Acad. Sci. U.S.A. 101, 16046–16051 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Bressler J. P., Olivi L., Cheong J. H., Kim Y., Bannona D. (2004) Ann. N.Y. Acad. Sci. 1012, 142–152 [DOI] [PubMed] [Google Scholar]
  • 77.Aisen P., Enns C., Wessling-Resnick M. (2001) Int. J. Biochem. Cell Biol. 33, 940–959 [DOI] [PubMed] [Google Scholar]
  • 78.Zhang S., Wang J., Song N., Xie J., Jiang H. (2009) Neurobiol. Aging 30, 1466–1476 [DOI] [PubMed] [Google Scholar]
  • 79.Watts R. J., Sarasa J., Loge F. J., Teel A. L. (2005) J. Environ. Eng. 131, 158–164 [Google Scholar]
  • 80.Wang X., Li G. J., Zheng W. (2006) Brain Res. 1097, 1–10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Salvatore M. F., Fisher B., Surgener S. P., Gerhardt G. A., Rouault T. (2005) Brain Res. Mol. Brain Res. 139, 341–347 [DOI] [PubMed] [Google Scholar]
  • 82.Miller G. W., Gainetdinov R. R., Levey A. I., Caron M. G. (1999) Trends Pharmacol. Sci. 20, 424–429 [DOI] [PubMed] [Google Scholar]
  • 83.Nass R., Hahn M. K., Jessen T., McDonald P. W., Carvelli L., Blakely R. D. (2005) J. Neurochem. 94, 774–785 [DOI] [PubMed] [Google Scholar]
  • 84.Levenson C. W., Cutler R. G., Ladenheim B., Cadet J. L., Hare J., Mattson M. P. (2004) Exp. Neurol. 190, 506–514 [DOI] [PubMed] [Google Scholar]
  • 85.Chen M. K., Lee J. S., McGlothan J. L., Furukawa E., Adams R. J., Alexander M., Wong D. F., Guilarte T. R. (2006) Neurotoxicology 27, 229–236 [DOI] [PubMed] [Google Scholar]
  • 86.Ramirez A., Heimbach A., Gründemann J., Stiller B., Hampshire D., Cid L. P., Goebel I., Mubaidin A. F., Wriekat A. L., Roeper J., Al-Din A., Hillmer A. M., Karsak M., Liss B., Woods C. G., Behrens M. I., Kubisch C. (2006) Nat. Genet. 38, 1184–1191 [DOI] [PubMed] [Google Scholar]
  • 87.Brown D. R. (2009) Biochem. Biophys. Res. Commun. 380, 377–381 [DOI] [PubMed] [Google Scholar]
  • 88.Olivares D., Huang X., Branden L., Greig N. H., Rogers J. T. (2009) Int. J. Mol. Sci. 10, 1226–1260 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Lin Y. T., Hoang H., Hsieh S. I., Rangel N., Foster A. L., Sampayo J. N., Lithgow G. J., Srinivasan C. (2006) Free Radic. Biol. Med. 40, 1185–1193 [DOI] [PubMed] [Google Scholar]
  • 90.Rand J. B., Johnson C. D. (1995) Methods Cell Biol. 48, 187–204 [DOI] [PubMed] [Google Scholar]
  • 91.Keen C. L., Ensunsa J. L., Clegg M. S. (2000) in Metal Ions in Biological Systems ( Sigel A., Sigel H. eds) pp.89–121, CRC Press, Boca Raton, FL: [PubMed] [Google Scholar]

Articles from The Journal of Biological Chemistry are provided here courtesy of American Society for Biochemistry and Molecular Biology

RESOURCES